Evidence map›Paper›PMID 42035091›Full record

ArticleMalaria journal2026

Prioritising in a crisis: what next for malaria research?

E G Chestnutt, M O Afolabi, U D'Alessandro, M Delves, R Gosling, G Jagoe, E Lasry, C Maiteki, R W Moon, E Oriero and 4 more

Abstract read
In one paragraph

Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

E G ChestnuttMalaria Consortium, London, UK.
M O AfolabiMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
U D'AlessandroMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
M DelvesMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
R GoslingMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
G JagoeMedicines for Malaria Venture, Geneva, Switzerland.
E LasryThe Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
C MaitekiNational Malaria Control Division, Ministry of Health, Kampala, Uganda.
R W MoonMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
E OrieroMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
C PittMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
F TadesseMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK.
J K TibenderanaMalaria Consortium, London, UK.
V B RaoMalaria Centre, London School of Hygiene and Tropical Medicine, London, UK. bhargavi.rao@lshtm.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global malaria control is entering a period of profound uncertainty, with earlier gains now stalling or reversing amid a rapidly deepening shortfall in programme and research funding. At the same time, parasite and vector resistance, changing transmission patterns driven by climate and urbanisation, and growing conflict and displacement are reshaping malaria epidemiology and undermining the effectiveness of core tools. In this context, there is an urgent need to reconsider how malaria research is prioritised, funded and conducted. Drawing on a diverse group of stakeholders, this Perspective argues that malaria research must adopt a dual mandate: protecting lives now while preparing programmes for the next generation of biological and systemic threats. We highlight three interlinked priorities. First, pragmatic, equity‑focused implementation and health‑systems research should be prioritised to optimise the effectiveness, efficiency and coverage of existing interventions, including through integrated delivery models and closer collaboration with affected communities and implementers. Second, sustained investment in innovation-such as next‑generation chemoprevention strategies, vaccines and monoclonal antibodies, novel vector control approaches, and digital or AI‑enabled surveillance-is essential, accompanied by operational research that addresses feasibility, cost and pathways to scale in real‑world conditions. Third, we highlight a critical research stream on sustainable and diversified financing, and on how data, economic evidence and political economy analysis can more effectively inform national and global decision‑making. By re‑orienting towards an impact‑driven, context‑sensitive and value‑for‑money research agenda, the malaria community can help stabilise fragile programmes, reduce the risk of resurgence and preserve momentum towards long-term malaria elimination in an era of constraint.

Indexed as

Biomedical ResearchCommunicable Disease ControlMalariaResearchHumansMalaria

Identifiers

PMID42035091
PMCPMC13112674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.